Literature DB >> 19949921

Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

Anna Maria Calcagno1, Suresh V Ambudkar.   

Abstract

Multidrug resistance (MDR) remains one of the key determinants in chemotherapeutic success of cancer patients. Often, acquired resistance is mediated by the overexpression of ATP-binding cassette (ABC) drug transporters. To study the mechanisms involved in the MDR phenotype, investigators have generated a variety of in vitro cell culture models using both multi-step and single-step drug selections. Sublines produced from multi-step selections have led to the discovery of several crucial drug transporters including ABCB1, ABCC1, and ABCG2. Additionally, a number of mechanisms causing gene overexpression have been elucidated. To more closely mimic in vivo conditions, investigators have also established MDR sublines with single-step drug selections. Here, we examine some of the multi-step and single-step selected cell lines generated to elucidate the mechanisms involved in the development of MDR in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19949921      PMCID: PMC3099236          DOI: 10.1007/978-1-60761-416-6_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  64 in total

1.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

Authors:  S K Rabindran; H He; M Singh; E Brown; K I Collins; T Annable; L M Greenberger
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

2.  Selection and maintenance of multidrug-resistant cells.

Authors:  M M Gottesman; C Cardarelli; S Goldenberg; T Licht; I Pastan
Journal:  Methods Enzymol       Date:  1998       Impact factor: 1.600

3.  Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.

Authors:  D A Scudiero; A Monks; E A Sausville
Journal:  J Natl Cancer Inst       Date:  1998-06-03       Impact factor: 13.506

4.  Gene rearrangement: a novel mechanism for MDR-1 gene activation.

Authors:  L A Mickley; B A Spengler; T A Knutsen; J L Biedler; T Fojo
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

5.  Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.

Authors:  J S Lee; S Scala; Y Matsumoto; B Dickstein; R Robey; Z Zhan; G Altenberg; S E Bates
Journal:  J Cell Biochem       Date:  1997-06-15       Impact factor: 4.429

6.  Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples.

Authors:  Lyn Mickley Huff; Zheng Wang; Angel Iglesias; Tito Fojo; Jong-Seok Lee
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.

Authors:  Vasil F Chekhun; Galina I Kulik; Olga V Yurchenko; Volodymyr P Tryndyak; Igor N Todor; Liliana S Luniv; Nadiya A Tregubova; Tamara V Pryzimirska; Beverly Montgomery; Nataliya V Rusetskaya; Igor P Pogribny
Journal:  Cancer Lett       Date:  2006-01-08       Impact factor: 8.679

8.  Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.

Authors:  G M Su; M W Davey; R A Davey
Journal:  Int J Cancer       Date:  1998-05-29       Impact factor: 7.396

Review 9.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

10.  Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1.

Authors:  T A Ince; K W Scotto
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  18 in total

1.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

2.  Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.

Authors:  Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.

Authors:  Joe Goldufsky; Stephen Wood; Behnam Hajihossainlou; Tooba Rehman; Omar Majdobeh; Howard L Kaufman; Carl E Ruby; Sasha H Shafikhani
Journal:  J Med Microbiol       Date:  2015-02       Impact factor: 2.472

4.  Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.

Authors:  Y Cheng; J Xu; J Guo; Y Jin; X Wang; Q Zhang; L Liu
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

5.  Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.

Authors:  Kowit Yu Chong; Chih-Jung Hsu; Tsai-Hsien Hung; Han-Shu Hu; Tsung-Teng Huang; Tzu-Hao Wang; Chihuei Wang; Chuan-Mu Chen; Kong Bung Choo; Ching-Ping Tseng
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.

Authors:  Yi-Jun Wang; Yun-Kai Zhang; Guan-Nan Zhang; Sweilem B Al Rihani; Meng-Ning Wei; Pranav Gupta; Xiao-Yu Zhang; Suneet Shukla; Suresh V Ambudkar; Amal Kaddoumi; Zhi Shi; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2017-03-14       Impact factor: 8.679

7.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

Review 8.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

9.  Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.

Authors:  Bhawna Sharma; Michelle L Varney; Sugandha Saxena; Lingyun Wu; Rakesh K Singh
Journal:  Cancer Lett       Date:  2016-01-12       Impact factor: 8.679

10.  Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts.

Authors:  Peggy Arthur; Nilkumar Patel; Sunil Kumar Surapaneni; Arindam Mondal; Aragaw Gebeyehu; Arvind Bagde; Shallu Kutlehria; Ebony Nottingham; Mandip Singh
Journal:  Toxicol Appl Pharmacol       Date:  2020-06-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.